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Abstract
Background: Accumulating evidence suggests a deleterious role for CD8+ T cells in multiple sclerosis (MS)
pathogenesis. We have recently reported that hepatocyte growth factor (HGF), a potent neuroprotective factor,
limits CD4+ T cell-mediated autoimmune neuroinflammation by promoting tolerogenic dendritic cells (DCs) and
subsequently regulatory T cells. Whether HGF modulates cell-mediated immunity driven by MHC class I-restricted
CD8+ T cells remains to be determined.
Methods: Here we examined whether HGF regulates antigen-specific CD8+ T cell responses using an established
model of murine cytotoxic T lymphocyte (CTL)-mediated killing.
Results: We found that HGF treatment of gp100-pulsed DCs reduced the activation of gp100-specific T cell receptor
(Pmel-1) CD8+ T cells and subsequent MHC class I-restricted CTL-mediated cytolysis of gp100-pulsed target cells.
The levels of perforin, granzyme B, IFN-γ, and the degranulation marker CD107a as well as Fas ligand were
decreased among CD8+ T cells, suggestive of a dual inhibitory effect of HGF on the perforin/granzyme B- and
Fas-based lytic pathways in cell-mediated cytotoxicity. Treatment of CD8+ T cells with concanamycin A, a potent
inhibitor of the perforin-mediated cytotoxic pathway, abrogated CTL cytotoxicity indicating that blockade of the
perforin-dependent killing is a major mechanism by which HGF diminished cytolysis of gp100-pulsed target cells.
Moreover, HGF suppressed the generation of effector memory CTLs.
Conclusions: Our findings indicate that HGF treatment limits both the generation and activity of effector CTL
from naïve CD8+ T cells. Complementary to its impact on CD4+ T-cell CNS autoimmunity and myelin repair, our
findings further suggest that HGF treatment could be exploited to control CD8+ T-cell-mediated, MHC I-restricted
autoimmune dysfunctions such as MS.
Keywords: Hepatocyte growth factor (HGF), Cytotoxic T lymphocytes (CTL), Immune modulation, Central nervous
system autoimmunity, Dendritic cells, Multiple sclerosis (MS), Immunological tolerance
Background
Multiple sclerosis (MS), a chronic autoimmune disorder
characterized pathologically by central nervous system
(CNS) inflammation, demyelination, and axonal damage,
has been traditionally attributed to self-reactive CD4+ T
lymphocytes that escape tolerance [1]. Growing evidence,
however, indicates that autoreactive CD8+ T cells, like their
CD4+ counterparts, contribute to the induction, progression,
and pathogenesis of autoimmune neuroinflammation [2,3].
Myelin-specific CD8+ T cells were reported to both aggra-
vate CD4+ T cell-mediated experimental autoimmune en-
cephalomyelitis (EAE) [4], an animal model for MS, and to
mediate autoimmune CNS disease on their own [5-7]. In
particular, adoptively transferred antigen-specific CD8+ T
cells were found to injure the CNS in models of CD8-
mediated EAE [5,6] or in mice that selectively express a
neo-self antigen in oligodendrocytes [8,9]. Using continuous
confocal imaging, axonal loss observed in these models was
shown to result from ‘collateral bystander damage’ by
autoaggressive, cytotoxic CD8+ T cells, targeting their
cognate antigen processed and presented by oligoden-
drocytes [10]. Histopathological and neurobiological
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studies in MS also suggest that CD8+ T cells hold an
active role in disease pathogenesis by targeting oligo-
dendrocytes and the myelin sheath [11].
Due to their ability to function as professional antigen-
presenting cells (APCs), CD11c+ myeloid DCs play an
undisputed role in inciting autoimmunity. In EAE, DCs
are critical APCs for the induction of both myelin-specific
CD4+ and CD8+ T cells, and are also a prominent compo-
nent of CNS-infiltrating cells [12,13]. However, other data
indicate that DCs play an important role in initiating
tolerance, and that tolerogenic DCs can suppress EAE
in vivo [14]. Current efforts for the treatment of auto-
immune pathogeneses requiring tolerance recovery are
focused in the identification of molecules that control
the development of tolerogenic DCs [15].
Hepatocyte growth factor (HGF) is a pleiotropic cyto-
kine with potent anti-inflammatory properties shown to
act as a potent regulator in multiple animal models of
immune-mediated disorders [16-19]. HGF has been
shown to govern the development of both human and
mouse tolerogenic DCs [20,21]. We recently demon-
strated that such a mechanism might account in part for
the beneficial action of CNS-restricted overexpression of
HGF in myelin oligodendrocyte glycoprotein (MOG)-in-
duced EAE by regulating CD4+ T cell-mediated auto-
immune responses to MOG [20]. Owing to its strong
immunoregulatory and neuroprotective/neurorepair prop-
erties [22,23], exogenously supplied HGF was recently fur-
ther shown to promote recovery in MOG-induced EAE by
modulating both the immune response mediated by CD4+
T cells and by promoting myelin repair and neural cell de-
velopment [24]. Because CD8+ T cells can further directly
mediate motor disability and axon injury in the demyeli-
nated CNS [25] and may actively contribute to neural
damage in MS or other CNS inflammatory and degenera-
tive disorders [26], it is important to understand whether
HGF could modulate the effector function of antigen-
specific CD8+ T cells.
To explore the effects of HGF on CD8+ T cell func-
tions we used an established in vitro model of cytotoxic
T-cell-dependent immunity. Our results showed that
HGF significantly decreased the generation of effector
cytotoxic gp100-petide T cell receptor (Pmel-1) CD8+ T
cells from naïve splenocytes. HGF greatly reduced the
production of inflammatory cytokines and cytolytic
enzymes by autoagressive CD8+ T cells, including inter-
feron (IFN)-γ, tumor necrosis factor (TNF), perforin,
and granzyme B. HGF further diminished the expression
of membrane-bound death receptor Fas ligand (FasL), a
non-redundant lytic mechanism with cytolytic granule
release in cytotoxic T lymphocyte (CTL)-mediated kill-
ing. CD8-enriched Pmel-1 splenocytes cultured with
HGF demonstrated a considerably lower level of cyto-
lytic activity, as measured by specific killing of antigen-
pulsed target cells. Finally, similar results were obtained
when HGF-treated CD11c+ DCs were cultured with
naïve purified Pmel-1 CD8+ T cells. These results sug-
gest that HGF reduces CTL responses via professional
APCs and may have important implications for CNS in-
flammatory diseases including MS.
Methods
Reagents
Human recombinant HGF (hrHGF) was supplied by T
Nakamura (Osaka University, Tokyo, Japan) [27]. Human
and murine HGF are cross-reactive. The dose of hrHGF
(30 ng/mL) used was chosen based on previous studies
analyzing the immunoregulatory effects of hrHGF on CD4+
T cell responses [20]. Lower doses were not as effective.
Cells and cultures
Murine EL-4 lymphoma cells were cultured in DMEM
complete medium (CM) supplemented with 10% fetal bo-
vine serum, 50 U/mL penicillin, 50 μg/mL streptomycin
and 2 mM L-glutamine (all from Invitrogen/Life Tech-
nologies). Splenocytes were derived from Pmel-1 T cell re-
ceptor (TCR) transgenic mice, whose TCR recognizes an
H-2Db-restricted epitope corresponding to amino acids
25–33 of murine and human gp100 (gp10025-33), a self-
tumor antigen. Approximately 90% of splenic CD3+ T
cells in Pmel-1 TCR mice are TCRVβ13+ CD8+ T cells and
demonstrate specificity for gp100 [28].
Purification of mouse splenic CD8+ T cells and
CD11c+ DCs
Mouse splenic CD8+ T cells were negatively selected using
an anti-mouse CD8+ T cell isolation kit (Miltenyi Biotec).
To obtain DCs, spleens were minced and incubated with
DNase (1 mg/mL) and Liberase HI (Roche) (0.5 mg/mL)
for 15 min at room temperature. Cold EDTA was added
to a final concentration of 20 mM, and cell suspensions
were incubated for 5 min at room temperature before
filtering through nylon mesh to remove tissue and cell
aggregates. Highly pure mouse splenic DCs were subse-
quently positively selected using anti-mouse CD11c col-
loidal superparamagnetic microbeads (Miltenyi Biotec), as
reported previously [20]. The purity of CD8+ and CD11c+
cells, confirmed by flow cytometry, was routinely >95%
and >85%, respectively.
CTL stimulation
Single-cell suspensions of pooled spleens from Pmel-1
mice were prepared by gently homogenizing the tissues
and passing them through a 70 μm Nylon cell strainer
(Falcon, BD Biosciences). Red blood cells were depleted
with ACK lysing buffer (BioWhittaker). Cells were resus-
pended in DMEM CM with 10 μg/mL gp10025-33 pep-
tide (KVPRNQDWL) for 1 h at 37°C. After being
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washed and counted, hrHGF (30 ng/mL) was added to
the cultures every other day starting on day 0. IL-2 (50
U/mL; PeproTech) was added to cultures at days 2 and
4. In certain experiments, purified DCs were treated or
not with hrHGF (30 ng/mL) for 24 h at 37°C. After be-
ing washed and counted, 2 × 106/mL DCs were resus-
pended in DMEM CM with 10 μg/mL gp10025-33 for
1 h at 37°C. Purified Pmel-1 TCR tg CD8+ T cells were
mixed with gp10025-33-pulsed autologous DCs at a ratio
of 10:1 for 5 days. IL-2 (50 U/mL) was added to cul-
tures at days 2 and day 4. Cells cultured for 5 days were
tested for functional and phenotypic assays. To evaluate
the role of perforin/granzyme-mediated cytotoxicity,
the effector cells were pre-treated with 1000 nM conca-
namycin A (Sigma-Aldrich) for 2 h prior to co-cultures
with target cells.
T cell proliferation assay
For antigen-specific stimulation of mouse CD8+ T cells,
highly purified DCs treated or not with hrHGF (1–50 ng/mL)
for 24 h at 37°C were cultured with gp10025-33 (10 μg/mL)
and naïve Pmel-1 TCR transgenic CD8+ T cells
for 5 days. Proliferation was measured by incorporation
of 3H-methylthymidine (1 μCi/well) during the last
16 h of culture using a filtermate harvester (Packard
Instrument Co.) and a 1450 microbeta liquid scintilla-
tion counter (PerkinElmer) and was expressed as
counts per minute (cpm).
Immunologic markers and flow cytometry
T cells or DCs were incubated in blocking solution (PBS
with 10% FCS) for 20 min on ice prior to staining
to block non-specific Fc-mediated interactions, and
then stained for 30 min at 4°C with FITC, PE, PerCP-
Cy5, or APC fluorochromes conjugated with antibodies
(Abs) (1:100) against: CD11c, c-Met, CD8, CD28, CD44,
CD62L, CD107a, CTLA-4, Fas-ligand (all Abs from
eBioscience), and LFA-1 (Biolegend), or appropriate
fluorochrome-conjugated, isotype-matched irrelevant
Abs to establish background fluorescence. For intracel-
lular staining of IFN-γ, TNF, perforin, and granzyme B
(all Abs from eBioscience), CD8+ T cells were stimulated
with PMA (1 μg/mL) plus ionomycin (500 ng/mL) in
the presence of GolgiStop (10 μg/mL) (BD), and then
fixed and permeabilized using BD Cytofix/Cytoperm
Plus Kit (BD Biosciences). CD3ζ (eBioscience) staining
was evaluated on fixed and permeabilized cells. Live,
apoptotic, and dead populations were defined on the
basis of 7-AAD Viability Staining Solution from eBioscience
according to the manufacturer’s instructions. Samples
were processed on a FACS Calibur flow cytometer
(Becton Dickinson) and analyzed using FlowJo analysis
software (Tree Star, Version 9.3.2).
Cytotoxicity assay
Functional activities of antigen-specific CTLs were ana-
lyzed with a DELFIA® cell cytotoxicity kit (PerkinElmer)
according to manufacturer’s instructions. Briefly, target
T-lymphocytic leukemia EL-4 cells were pulsed with
10 μg/mL gp10025-33 for 1 h at 37°C in DMEM CM, and
then washed. EL-4 (1 × 105 cells) were labelled with 50 μM
of fluorescence-enhancing ligand bis(acetoxymethyl)2,2′:
6′,2′′-terpyridine-t,6′′-dicarboxylate (BATDA) for 30 min
at 37°C. After washing, 5 × 103/well labelled cells were
mixed with antigen-specific CTLs at the indicated ratio in
96-well plates. Plates were incubated for 4 h at 37 °C. A
total of 20 μL of supernatant were harvested from each well
and added to wells containing 200 μL of 50 μM Europium
solution (Aldrich Chemical) in 0.3 M acetic acid (pH 4).
Plates were shaken for 15 min at room temperature and
the fluorescence of the Europium-TDA (Eu) chelates
formed was quantitated in a time-resolved fluorometer
(DELFIA 1234). All assays were performed in triplicates.
Spontaneous release was determined as Eu detected in the
supernatant of targets incubated in the absence of effector
cells. Maximum release was determined as Eu detected in
the supernatants of target cells incubated with lysis buffer
instead of effectors. Percent specific lysis was calculated ac-
cording to the formula: (experimental release - spontaneous
release)/(maximum release - spontaneous release) × 100.
Statistical analysis
Statistical comparisons were done using Student’s t-tests.
P values <0.05 were considered to be statistically signifi-
cant. All the statistical analyses were performed by
GraphPad Prism for Mac, Version 5.0.
Results
HGF limits effector Ag-specific CTL generation
In order to assess the capacity of HGF to modulate the gen-
eration of antigen-specific CD8+ T cells, Pmel-1 TCR trans-
genic splenocytes were stimulated with gp10025-33 for 1 h,
and then cultured with IL-2 alone or in combination with
HGF for 5 days. Five days after antigen stimulation with
gp10025-33, Pmel-1 splenocyte cultures showed >95% of
IL-2 expanded CD8+ T cells (Additional file 1: Figure S1a).
As shown by 7AAD staining, a similar percentage of
antigen-activated Pmel-1 CD8+ T cells underwent death
5 days after gp10025-33 stimulation when cultured in the ab-
sence or presence of HGF (Additional file 1: Figure S1b).
These data indicate that HGF has no influence on the via-
bility of the CD8+ T cells during their expansion. At day 0,
naïve CD8+ T cells showed a CD62LhiCD44low phenotype
prior to gp10025-33 stimulation (Figure 1a, left panel). After
5 days of stimulation, splenocyte cultures receiving HGF
maintained a significantly higher percentage of naïve
CD62LhiCD44low CD8+ T cells (Figure 1a, right panel) than
splenocytes cultured in absence of HGF (Figure 1a, middle
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panel). Augmented naïve CD62LhighCD44low phenotype
by CD8+ T cells was maintained throughout the entire
5 days of effector generation when incubated with HGF
(Figure 1b). These results suggest that HGF may inhibit
activation of antigen- and cytokine-stimulated T cells
and thus may limit the generation of effector and cen-
tral memory CD8+ T cells. HGF supplementation did
not decrease the expression of T-cell co-stimulatory
molecule CD28 on CD8+ T cells (Figure 1c) but was
found to upregulate expression of the co-inhibitory re-
ceptor cytotoxic T-lymphocyte antigen 4 (CTLA4) by
day 3- to 5-cultured CD8+ T cells (Figure 1c), a mech-
anism likely accounting for the apparent reduced
effector and central memory CD8+ T cell generation
over-time.
HGF limits inflammatory cytokine and cytotoxic effector
molecule production by activated CD8+ T cells
Since HGF maintained the naïve phenotype of T cells fol-
lowing antigen stimulation, we next examined whether
HGF could modulate the effector function of antigen-
specific CD8+ T cells. Five days following the initiation
of Pmel-1 T-cell cultures, we evaluated the expression of
indispensable inflammatory cytokines and content of
cytotoxic molecules by T cells cultured in IL-2 alone or
in combination with HGF, following antigen-specific
Figure 1 HGF limits antigen-specific CD8+ T cell activation. Splenocytes from Pmel-1 transgenic mice were stimulated in vitro with gp10025-33
(10 μg/mL) for 1 h, followed by addition of IL-2 alone or a combination of IL-2 and HGF cytokines for 5 additional days. (a) HGF is effective in
maintaining naïve CD62LhiCD44low CD8+ T cells. T cells were analyzed for the expression of CD44 and CD62L by flow cytometry (n = 3 mice per
group). At day 0, CD8+ T cells showed a naïve CD62LhiCD44low phenotype prior to gp10025-33 stimulation (a, left panel). At day 5, splenocytes
cultured with HGF had a significantly higher percentage of naïve CD62LhiCD44low CD8+ T cells (a, right panel) than splenocytes cultured in
absence of HGF (a, middle panel). Representative contour plots are shown. (b) Comparable data were detected on each day for all 5 days tested.
(c) Flow cytometry analysis of effector cells showed that HGF increased the amount on a per cell basis of CTLA4 starting at day 3 but not CD28
molecules, as indicated by comparative geometric mean of fluorescence (GMEAN) ± SEM of three independent experiments. At day 5, CD8+
T cells were analyzed for the expression of CTLA4 by flow cytometry (n = 3 mice per group) (right panel). Final GMEAN values are the result of
the ratio between the GMEAN obtained with the experimental antibody and the isotype control. *P <0.05 by Student’s t-test. Live cells were
selected based on gating forward and side scatter. All data were obtained from three independent experiments with similar results.
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stimulation. As shown in Figure 2a, addition of HGF de-
creased the expression of IFN-γ, granzyme B, and perforin.
Intracellular cytokine staining of antigen-stimulated day 5-
cultured CD8+ T cells showed that HGF not only de-
creased the number of T cells producing IFN-γ, granzyme
B, and perforin (Figure 2a), but also decreased the amount
of IFN-γ, granzyme B, and perforin production on a per
cell basis, as indicated by comparative geometric mean
fluorescence intensities (GMEAN) (Figure 2b). Similar
flow cytometry profiles were observed 4 h following the
initiation of T-cell cultures with gp10025-33-pulsed EL-4
cells as targets (Additional file 2: Figure S2a, b). This latter
effects could not be attributed to changes in cell size, as
CD8+ T cells cultured in the presence or absence of HGF
maintained the same physical cell size as investigated by
forward scatter analyses (Additional file 2: Figure S2c).
Treatment with HGF reduces the CD8+ cytotoxic-T-
lymphocyte response
Five days following the initiation of Pmel-1 T-cell cul-
tures, we evaluated the expression of other CTL-
associated effector molecules by T cells cultured in IL-2
alone or in combination with HGF. HGF treatment was
associated with reduced content of granzyme B, perforin,
and IFN-γ (Figure 3a, b). In addition, HGF also de-
creased the production of the Th1 cytokine TNF by
antigen-specific CD8+ T cells. Moreover, HGF reduced
the expression of the death receptor ligand FasL, a non-
redundant lytic mechanisms with cytolytic granule re-
lease in CTL-mediated killing. Finally, the cell surface
molecule lymphocyte function-associated antigen 1
(LFA-1), an important contributor to CTL activation
and CTL-mediated direct cell lysis was also significantly
reduced. Taken together, these data suggest that HGF
significantly reduces both perforin/granzyme B- and Fas-
dependent cytotoxicity during an antigen-specific T-cell
response. Comparable flow cytometry profiles were de-
tected 4 h following the initiation of T-cell cultures with
gp10025-33-pulsed EL-4 target cells (Additional file 3:
Figure S3a, b). Noticeably, HGF treatment reduced cell
surface mobilization of CD107a, a marker commonly
used to measure of CTL activity. CD107a is usually
found in vesicle membranes, but during CTL-target cell
interaction it is mobilized to the cell surface.
HGF restrains cytotoxicity of antigen-specific CD8+ cells
Since HGF sustains the naïve activation phenotype of T
cells following antigen stimulation and decreases the re-
lease of cytolytic granule and pro-inflammatory cytokine
mediators and expression of FasL, we next examined
whether HGF could modulate the effector function of
antigen-specific CD8+ T cells. We tested the cytolytic
capacity of the cultured T cells using gp10025-33-pulsed
EL-4 cells as targets. In these experiments, CD8+ T cells
Figure 2 HGF reduces inflammatory cytokine and cytolytic enzyme production by activated CD8+ T cells. Pmel-1 splenocytes were
cultured for 5 days in IL-2 alone or in combination with HGF, following antigen-specific stimulation. (a and b) Intracellular cytokine staining of
day 5-cultured CD8+ T cells showed that addition of HGF not only decreased (a) the number of CD8+ T cells producing IFN-γ, granzyme B, and
perforin but also decreased (b) the amount of IFN-γ, granzyme B, and perforin production on a per cell basis, as indicated by comparative
geometric mean of fluorescence (GMEAN) ± SEM of three independent experiments. Final GMEAN values are the result of the ratio between the
GMEAN obtained with the experimental antibody and the isotype control. Representative contour plots (a) and histograms (b) are shown.
*P <0.05 by Student’s t-test. All data were obtained from three independent experiments with similar results.
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cultured in HGF demonstrated dramatically reduced
specific cytotoxicity compared with CD8+ T cells cul-
tured alone (Figure 4a). This decreased cytolytic capacity
of CD8+ T cells could be explained by a difference in
perforin, granzyme B, or LFA-1 expression, as HGF sig-
nificantly affected expression of all molecules (Figures 2
and 3). We found that concanamycin A, an inhibitor of
the perforin-based cytotoxic pathway, almost completely
abolished target cell destruction by CTLs (Figure 4b),
stressing the importance of this pathway for immediate
lytic function mediated by Pmel-1 CD8+ T cells. HGF
pretreatment did not, however, further reduce the re-
sidual killing observed using concanamycin A-treated
CTLs. These results argue that HGF mainly limits the
cytotoxic, anti-tumor function of Pmel-1 CD8+ T cells in
a perforin-dependent manner in our experimental set-
tings. Impaired CTL killing was further not associated
with changes in CD3ζ expression, a crucial molecule for
T-cell activation upon antigen recognition (Figure 4c).
HGF limits CTL responses by modulating APC functions
We previously showed that dendritic cells (DCs), required
for initiating CTL responses [29], are vulnerable to HGF
treatment [20], which can contribute to diminished CTL
responses. To address whether this potential mechanism
may account for reduced priming of antigen-specific
CD8+ T cell responses from Pmel-1 splenocyte cultures,
we assessed the effect of HGF on the ability of antigen
donor DCs cells to prime naïve antigen-specific CD8+ T
cells. Highly purified CD11c+ DCs were cultured for 24 h
Figure 3 HGF decreases effector molecules by activated CD8+ T cells. Splenocytes from Pmel-1 mice were cultured in IL-2 alone or in
combination with HGF for 5 days, following antigen-specific stimulation with gp10025-33. (a and b) Flow cytometry analysis of effector cells
showed that HGF decreased both (a) the number of CD8+ T cells expressing TNF, FasL, and LFA-1 and (b) the amount on a per cell basis of
these molecules that play an important role in CTL cytotoxicity, as indicated by comparative geometric mean of fluorescence (GMEAN) ± SEM of
three independent experiments. Final GMEAN values are the result of the ratio between the GMEAN obtained with the experimental antibody
and the isotype control. Representative contour plots (a) and histograms (b) are shown. *P <0.05 by Student’s t-test. All data were obtained from
three independent experiments with similar results.
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with either HGF or vehicle and then co-cultured with
purified Pmel-1 CD8+ T cells in the presence of IL-2 and
gp10025-33 for 5 days. In contrast to DCs, CD8
+ T cells did
not express the HGF receptor c-Met (Additional file 4:
Figure S4). At day 5, CD8+ T cell measurement of [3H]
thymidine incorporation by these cells showed that HGF-
treated DCs induced low levels of CD8+ T-cell prolifera-
tion when compared to those obtained with untreated
DCs (Figure 5a). We tested the cytolytic capacity of the
CD8+ T cells co-cultured in the presence of HGF- or
vehicle-treated DCs using gp10025-33-pulsed EL-4 target
cells. As shown in Figure 5b, CD8+ T cells co-cultured
with HGF-treated DCs demonstrated dramatically lower
specific cytotoxicity compared to T cells co-cultured with
control DCs. As expected, CTLs generated in the presence
of HGF-treated DCS were associated with reduced expres-
sion of cytolytic markers, such as perforin, granzyme B,
and FasL. Altogether, these results indicate that HGF acts
directly on DCs by reducing their ability to both generate
and prime antigen-specific CD8+ T cell responses.
Discussion
HGF is a multifunctional cytokine that blunts inflamma-
tion in a variety of inflammatory T-cell-mediated disease
models, suggesting that HGF suppresses a common in-
flammatory process. In MOG-induced EAE, a common
model of MS primarily mediated by encephalitogenic
CD4+ T cell responses and characterized by demyelin-
ation and axonal loss [30], we have previously demon-
strated that overexpression of neuronal HGF attenuated
disease progression in part via anti-inflammatory signals
[20]. Using this MS model, we established that HGF ex-
erts an anti-inflammatory effect through the generation
of tolerogenic DCs and the subsequent suppression of
autoreactive peripheral Th1 and Th17 cells, leading to
reduced CD4+ T cell-mediated CNS injury. Whether
HGF modulates cell-mediated immunity driven by MHC
class I-restricted CD8+ T cells remained unknown.
In addition to pathogenic CD4+ T cells, multiple ob-
servations support the idea that CD8+ T cells are in-
volved in pathogenesis of CNS autoimmunity, as active
Figure 4 HGF restrains cytotoxicity of antigen-specific CD8+ cells in a perforin-dependent manner. (a) The cytolytic capacity of day
5-cultured CD8+ T cells was tested using EL-4 cells as targets. CD8+ T cells isolated from splenocytes cultured with HGF demonstrated dramatically
lower specific cytotoxicity compared to CD8+ T cells isolated from splenocytes cultured alone (right panel). gp10025-33-stimulated CD8
+ T cells
did not lyse non-pulsed EL-4 target cells (left panel). Results are the mean ± SEM of three independent experiments carried out in triplicates.
(b) The 4 h cytotoxicity assays (effector : target ratio, 20 : 1) were performed with CTLs pretreated with (+) or without (−) 1000 nM of concanamycin
A (ConA) for 2 h. Data are represented as percent of specific lysis above the specific lysis of the EL-4 targets without adding exogenous peptide.
A representative experiment of two is shown. *P <0.05 by Student’s t-test. (c) Flow cytometry analysis of day 5-cultured CD8+ T cells showed that
addition of HGF did not decrease the level of expression of CD3ζ on a per cell basis, as indicated by comparative geometric mean of fluorescence
(GMEAN). Final GMEAN values are the result of the ratio between the GMEAN obtained with the experimental antibody and the isotype control.
Representative histograms of day 0 and 5 of three independent experiments with similar results are shown.
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contributors to the development of neuroinflammation.
In MS, CD8+ T cells outnumber by far CD4+ T cells
in both acute and chronic inflammatory lesions. In
addition, while CD4+ T cells show a primarily perivascu-
lar distribution, CD8+ T cells can be detected in the par-
enchyma [31,32]. Although normally poorly expressed,
MHC class I molecules are highly expressed within the
MS lesion on astrocytes, oligodendrocytes, and neurons,
suggesting that CD8+ T cells could be directly engaging
these cell types [33-36]. Using an established model of
murine CTL-mediated killing we have here examined
whether HGF could regulate autoaggressive, cytotoxic
CD8+ T cell responses.
In this study, we found that HGF treatment of DCs
reduced the generation and functions of cytotoxic ef-
fector CD8+ T lymphocytes and subsequent MHC class
I-restricted CTL-mediated cytolysis of target cells. The
development of naïve cytotoxic CD8+ T cells into CTLs
requires specific recognition of antigen:MHC class I
complexes on professional APCs in conjunction with co-
stimulatory signals. Secondary recognition of antigen:
MHC class I complexes on a target cell by a CTL leads
to the death of the target cell. Our findings indicate that
HGF treatment interfered with the development of
autoagressive CTLs and not their capacity to recognize
their target cells. In particular, we found that HGF treat-
ment increased the levels of the inhibitory counter-
receptor CTLA4 molecules expressed on CD8+ T cells
but did not affect the expression of the CD3ζ molecules.
CTLA4-mediated negative co-stimulation together with
other regulatory mechanisms mediated by tolerogenic
APCs likely accounts for maintenance of high frequen-
cies of naïve CTL precursors incapable of cytotoxicity in
splenocyte cultures supplemented with HGF.
CTLs mediate the killing of target cells via two major
pathways, a granule-dependent (perforin/granzyme B)
and independent (FasL induced cell death) mechanism.
Here we found that HGF treatment decreased the levels
of the effector CTL molecules IFN-γ, TNF, perforin, and
granzyme B as well as the expression of CD107a, a
Figure 5 HGF limits CTL responses by modulating APC functions. Highly purified CD11c+ DCs were cultured for 24 h with either HGF or
vehicle and then co-cultured with purified Pmel-1 CD8+ T cells in the presence of IL-2 and gp10025-33 for 5 days. (a) HGF-treated DCs induced
low levels of CD8+ T-cell proliferation, as measured at day 5 by [3H] thymidine incorporation. Values are expressed as counts per minute (cpm).
Data are representative of three independent experiments with similar results. *P <0.05; **P <0.01 by Student’s t-test. (b) CD8+ T cells co-cultured
with HGF-treated DCs demonstrated dramatically reduced specific cytotoxicity compared with T cells co-cultured with control PBS-treated DCs
(right panel). gp10025-33-stimulated CD8
+ T cells did not lyse non-pulsed EL-4 target cells (left panel). Results are the mean ± SEM of three
independent experiments carried out in triplicates.
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marker of CD8+ T-cell degranulation following stimula-
tion. Using a potent inhibitor of the perforin-based cyto-
toxic pathway, concanamycin A, we found that HGF
potently inhibits CTL-mediated killing through inter-
ference with the granule exocytosis pathway. Our data
further revealed that HGF treatment reduced CTL-
bound FasL expression on CD8+ T cells, suggestive of an
action of HGF on the dual perforin/granzyme B- and
Fas-based CTL-mediated cytotoxicity. As both the per-
forin/granzyme B-dependent granule exocytosis pathway
[37-41] and the Fas signaling [42,43] have been impli-
cated as potential mechanisms in oligodendrocyte and/
or axonal injury and demyelination in MS, our findings
taken together suggest that HGF might be effective in a
potential therapeutic approach to reduce CTL effector
function in CTL-mediated human autoimmune disorder
of the CNS.
Conclusions
Altogether, our findings indicate that HGF treatment
limits both the generation and effector functions of
CTLs. Complementary to its impact on CD4+ T-cell CNS
autoimmunity, our findings further suggest that HGF treat-
ment could be exploited to control CD8+ T-cell-mediated,
MHC I-restricted autoimmune dysfunctions such as MS.
By coupling immunosuppressive properties on both CD4+
and CD8+ T cell effector responses and neurorepair actions,
HGF appears thus to be a promising candidate for the
treatment of inflammatory demyelinating neurodegenera-
tive diseases such as MS. One must, however, point out that
such observations are preliminary, and do not establish the
safety of HGF administration over the long term, which
may include potential adverse events. In particular, add-
itional research is warranted to evaluate the impact of HGF
therapy in anti-tumor immunity as the potent immune
inhibition exerted by HGF may help tumor cells to
escape from immune surveillance.
Additional files
Additional file 1: Figure S1. HGF does not affect in vitro-expanded
CD8+ T cell viability. (a) Five days after stimulation with gp10025-33,
Pmel-1 splenocyte cultures showed >95% of IL-2 expanded CD8+ T cells.
(b) A similar percentage of antigen-activated Pmel-1 CD8+ T cells
underwent death 5 days after gp10025-33 stimulation when cultured in
the absence or presence of HGF, as shown by 7AAD staining.
Representative contour plots are shown. All data were obtained from
three independent experiments with similar results.
Additional file 2: Figure S2. HGF restrains CTL effector molecule
expression. In vitro-expanded CD8+ T cell were cultured for 4 h with
gp10025-33-pulsed EL-4 target cells. (a and b) Intracellular cytokine
staining of CD8+ T cells showed that addition of HGF to Pmel-1
splenocyte cultures not only decreased (a) the number of CD8+ T cells
producing IFN-γ, granzyme B, and perforin but also decreased (b) the
amount of IFN-γ, granzyme B, and perforin production on a per cell basis,
as indicated by comparative geometric mean of fluorescence. (c) Forward
scatter analyses of CD8+ T cells indicate that HGF supplementation did
not affect cell size. Data are presented overlapping the control analysis.
Representative contour plots (a) and histograms (b, c) are shown. All data
were obtained from three independent experiments with similar results.
Additional file 3: Figure S3. HGF dampens effector molecules by
activated CD8+ T cells. In vitro-expanded CD8+ T cell were cultured for
4 h with gp10025-33-pulsed EL-4 target cells. (a and b) Flow cytometry
analysis of effector cells showed that addition of HGF to Pmel-1
splenocyte cultures decreased both (a) the number of CD8+ T cells
expressing CD107, TNF, FasL, and LFA-1 and (b) the amount on a per cell
basis of these molecules that play an important role in CTL cytotoxicity,
as indicated by comparative geometric mean of fluorescence.
Representative contour plots (a) and histograms (b) are shown. All data
were obtained from three independent experiments with similar results.
Additional file 4: Figure S4. DCs but not CD8+ T cells show
cell-surface expression of the HGF receptor c-Met. Expression of c-Met
at the cell surface of CD11c+ DCs and CD8+ T cells was examined by
flow cytometry. Illustrative histograms depict the expression of c-Met
(open histograms) and control staining with isotype-matched antibody
(shaded histograms).
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